HC Wainwright & Co. maintained its Dentsply Sirona [XRAY] rating to the equivalent of Neutral but changed the price target to $55.0 from $49, in a research note dated 2021-01-05. That figure represents around a 2.33% premium from where the company’s shares closed on Monday. Other analysts also revised their coverage, with Barclays’s analysts downgrading the shares from “an Equal weight” rating to “an Underweight” rating in a research note to investors issued in mid November. Meanwhile, H.C. Wainwright had maintained its rating on XRAY to the earlier “Neutral” rating, in a research note produced for clients November 09, 2020. In addition, there was an upgrade from Guggenheim on October 22, 2020. The rater changed XRAY from “a Neutral” to “a Buy”.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is DENTSPLY SIRONA Inc. [NASDAQ:XRAY] a Good Buy Right Now?
It should be noted that XRAY technical indicators for short, intermediate as well as long term progress have placed an overall average of 96% as Buy. The average signal changed from 88% Buy in the last week and compares with 100% Buy in the past month. Data from DENTSPLY SIRONA Inc.’s Trend Spotter indicated that the signals were Bullish. The stock current average is 1.01 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 1.26 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 1.23 million shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
XRAY Price Performance
On Wall Street, DENTSPLY SIRONA Inc. [NASDAQ:XRAY] finished Monday’s session up 2.65% at $53.75. The stock went up to $54.95 at the same session while its lowest single day price was $52.64. In the last five days, it saw a rise of about 3.72%, DENTSPLY SIRONA Inc. shares gained by almost 2.65% since the beginning of the year. However, the share price has dropped to as low as -11.70% below its one year high. On 01/04/21, the company shares recorded $54.95, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $52.64. The company’s shares have declined by -4.53% in the past year. The 50-day SMA achieved is $50.70 while the 200-day SMA is $44.97. Volume gained to 2.21 million from 0.61 million in the previous session.
XRAY Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 52.61 level, and in case of violation of this particular level, it will cause more drop to 51.47 level. On the upper level, 56.09 is still the key resistance. The stock may increase to the subsequent resistance at 54.92. The Relative Strength Index (RSI) pinned on the 14-day chart is 59.16, implying a neutral technical stance while the MACD stands at 0.10, meaning price will decrease in the next trading period. Percent R indicator moved to 30.00%, implying 30.00 price movement. Stochastic %K at 49.66% suggest selling the stock.
What is the short interest in DENTSPLY SIRONA Inc.?
Short interest in the DENTSPLY SIRONA Inc. stock has surged, increasing by 0.89 million shares to total 3.23 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 4.12 million, data from Yahoo Finance shows. The decrease of -27.55% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 1.68% of the overall float for the stock.
DENTSPLY SIRONA Inc.’s Biggest Shareholders: Who Owns DENTSPLY SIRONA Inc. [XRAY]?
Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 23,043,995 shares or roughly 10.54% of the outstanding XRAY shares. This means their shares have reduced by -1,035,474 from the 23,043,995 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Generation Investment Management updated stake is worth $984,360,995. Details in the latest 13F filings reveal that Artisan Partners LP acquired their 23.37% stake valued at $788,470,067 while BlackRock Fund Advisors cut theirs at $549,252,157. During the last quarter, Artisan Partners LP raised 2,935,431 of its shares in DENTSPLY SIRONA Inc. while BlackRock Fund Advisors sold -386,916 shares. The SSgA Funds Management, Inc.’s holdings currently number 10,013,920 shares at $538248200.0. According to the firm’s last 13F report, T. Rowe Price Associates, Inc. shares in the company at filing stood at 9,578,773 shares, roughly $487,463,758.
XRAY Earnings Forecast For The Current Quarter
DENTSPLY SIRONA Inc. [XRAY] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $995.95M and an earnings per share of $0.64 for Dec 2020. Looking further ahead, the company is expected to report revenue of $882.57M at an EPS of $0.5 for Mar 2021. The estimates represent downside of 15.70% and 47.83% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
XRAY Earnings Estimates For The Current Year
For the financial year, DENTSPLY SIRONA Inc. [NASDAQ:XRAY] is expected to bring in revenue of $3.26B. The returns are nearly $-770.0 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 1.56, lower than that of FY19 by -$0.89. Estimates put this year’s earnings growth at -36.30%, 50.00% for the next, and at an annual 5.70% over the next 5-year period. As for sales, forecasts are for a decrease of -19.10% in the current fiscal year and a further 15.70% over the following year.
